News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FibroGen, Inc. to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology Kidney Week 2012


11/1/2012 8:31:35 AM

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012. The annual meeting will be held October 30 – November 4, 2012, in San Diego, California. Full abstracts can be viewed online at http://www.asn-online.org/education/kidneyweek/archives/.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES